Skip Navigation

Cardiovascular Research 2007 74(1):8-10; doi:10.1016/j.cardiores.2007.02.011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Van Gelder, I. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Gelder, I. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Rhythm control for atrial fibrillation: Non-channel antiarrhythmic drugs are en vogue

Isabelle C. Van Gelder*

Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands

* Tel.: +31 (0)50 3611327; fax: +31 (0)50 3614391. Email address: I.C.van.Gelder@thorax.umcg.nl

Received 12 February 2007; accepted 12 February 2007

The first 10% of the full text of this article appears below.

See article by Shiroshita-Takeshita et al. (pages 75–84) in this issue.

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Independent risk factors for AF are chronic heart failure and hypertension [1]. The incidence and prevalence of AF increase with the severity of chronic heart failure. Although recent trials showed that rate control can be adopted as first choice therapy [2], rhythm control still is the primary goal. Whether this also holds for patients with chronic heart failure is at present unsettled, but obviously, these patients would benefit most from sinus rhythm since with restoration and maintenance of sinus rhythm, left ventricular function, exercise capacity and maximal oxygen consumption may improve. At present, the cornerstone for rhythm-control therapy is serial ion-channel antiarrhythmic drug treatment with or . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
S. Ahmed, H. J. G. M. Crijns, and I. C. Van Gelder
Treatment With Amiodarone to Prevent Atrial Fibrillation--Reply
JAMA, March 11, 2009; 301(10): 1020 - 1020.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
P. Dorian and B. N. Singh
Upstream therapies to prevent atrial fibrillation
Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Sakabe, A. Shiroshita-Takeshita, A. Maguy, C. Dumesnil, A. Nigam, T.-K. Leung, and S. Nattel
Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling
Circulation, November 6, 2007; 116(19): 2101 - 2109.
[Abstract] [Full Text] [PDF]